User:Betsy Johns/Sandbox 1
From Proteopedia
(Difference between revisions)
Line 34: | Line 34: | ||
<scene name='87/877509/Dgat_bound_with_dag/1'>DAG</scene> enters the active site through the lateral gate located in the lipid bilayer of the membrane. This <scene name='87/877509/Surface_active_site/2'>Active Site Tunnel</scene> or lateral gate is a bent and hydrophobic channel that allows for hydrophobic linear or curvilinear molecules to enter. The lateral gate channel is designed to allow for the entrance of DAG and the exit of a triacylglyceride. This channel is also lined with the hydrophobic residues Phe342, Leu261, Val381, and Asn378. Once within the channel, DAG is positioned in close proximity to the bound Acyl-CoA and the catalytic His415. | <scene name='87/877509/Dgat_bound_with_dag/1'>DAG</scene> enters the active site through the lateral gate located in the lipid bilayer of the membrane. This <scene name='87/877509/Surface_active_site/2'>Active Site Tunnel</scene> or lateral gate is a bent and hydrophobic channel that allows for hydrophobic linear or curvilinear molecules to enter. The lateral gate channel is designed to allow for the entrance of DAG and the exit of a triacylglyceride. This channel is also lined with the hydrophobic residues Phe342, Leu261, Val381, and Asn378. Once within the channel, DAG is positioned in close proximity to the bound Acyl-CoA and the catalytic His415. | ||
- | === Active Site === | + | === Active Site Structure === |
<scene name='87/877509/Active_site_zoomed_out/1'>Active Site Overview</scene> | <scene name='87/877509/Active_site_zoomed_out/1'>Active Site Overview</scene> |
Revision as of 19:14, 12 April 2021
Diacylglycerol acyltransferase, DGAT
|
References
- ↑ 1.0 1.1 Wang L, Qian H, Nian Y, Han Y, Ren Z, Zhang H, Hu L, Prasad BVV, Laganowsky A, Yan N, Zhou M. Structure and mechanism of human diacylglycerol O-acyltransferase 1. Nature. 2020 May;581(7808):329-332. doi: 10.1038/s41586-020-2280-2. Epub 2020 May, 13. PMID:32433610 doi:http://dx.doi.org/10.1038/s41586-020-2280-2
- ↑ 2.0 2.1 Sui X, Wang K, Gluchowski NL, Elliott SD, Liao M, Walther TC, Farese RV Jr. Structure and catalytic mechanism of a human triacylglycerol-synthesis enzyme. Nature. 2020 May;581(7808):323-328. doi: 10.1038/s41586-020-2289-6. Epub 2020 May, 13. PMID:32433611 doi:http://dx.doi.org/10.1038/s41586-020-2289-6
- ↑ 3.0 3.1 Denison H, Nilsson C, Lofgren L, Himmelmann A, Martensson G, Knutsson M, Al-Shurbaji A, Tornqvist H, Eriksson JW. Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial. Diabetes Obes Metab. 2014 Apr;16(4):334-43. doi: 10.1111/dom.12221. Epub 2013 Oct, 31. PMID:24118885 doi:http://dx.doi.org/10.1111/dom.12221
- ↑ 4.0 4.1 Stephen J, Vilboux T, Haberman Y, Pri-Chen H, Pode-Shakked B, Mazaheri S, Marek-Yagel D, Barel O, Di Segni A, Eyal E, Hout-Siloni G, Lahad A, Shalem T, Rechavi G, Malicdan MC, Weiss B, Gahl WA, Anikster Y. Congenital protein losing enteropathy: an inborn error of lipid metabolism due to DGAT1 mutations. Eur J Hum Genet. 2016 Aug;24(9):1268-73. doi: 10.1038/ejhg.2016.5. Epub 2016 Feb , 17. PMID:26883093 doi:http://dx.doi.org/10.1038/ejhg.2016.5
- ↑ Rebello CJ, Greenway FL. Obesity medications in development. Expert Opin Investig Drugs. 2020 Jan;29(1):63-71. doi:, 10.1080/13543784.2020.1705277. Epub 2019 Dec 19. PMID:31847611 doi:http://dx.doi.org/10.1080/13543784.2020.1705277
- ↑ Scott SA, Mathews TP, Ivanova PT, Lindsley CW, Brown HA. Chemical modulation of glycerolipid signaling and metabolic pathways. Biochim Biophys Acta. 2014 Aug;1841(8):1060-84. doi:, 10.1016/j.bbalip.2014.01.009. Epub 2014 Jan 15. PMID:24440821 doi:http://dx.doi.org/10.1016/j.bbalip.2014.01.009
Student Contributors
- Betsy Johns
- Elise Wang
- Tyler Bihasa